Carafate Dosing for Ulcers
For active duodenal ulcers, the recommended dose of sucralfate (Carafate) is 1 gram four times daily, taken on an empty stomach (one hour before meals and at bedtime), continued for 4 to 8 weeks. 1
Standard Dosing Regimen
The FDA-approved dosing for duodenal ulcer treatment is:
- 1 gram (10 mL/2 teaspoons of suspension or one tablet) four times per day
- Administered on an empty stomach
- Timing: typically 1 hour before meals and at bedtime
- Duration: 4 to 8 weeks unless healing is demonstrated earlier by endoscopy 1
Clinical Evidence Supporting This Dose
The 1 gram four times daily regimen has been extensively validated:
- Healing rates at 8 weeks: 66-76% compared to 39-53% with placebo 1, 2
- Significant improvement seen as early as 2 weeks (16-18% vs 6-7% placebo) 1, 2
- This dosing schedule demonstrated superiority over placebo at all time points (2,4, and 8 weeks) 2
Alternative Dosing Schedule
A twice-daily regimen of 2 grams (on waking and at bedtime) is equally effective and may improve compliance 3:
- Healing rates at 4 weeks: 79% (2g BID) vs 72% (1g QID)
- Cumulative healing at 8 weeks: 85% vs 80%
- This more convenient schedule is particularly useful for patients with adherence concerns
Important Administration Details
- Take on an empty stomach: Sucralfate requires an acidic environment to form its protective barrier at the ulcer site 1
- Antacid timing: If antacids are needed for pain relief, separate them by at least 30 minutes from sucralfate doses 1
- Duration matters: While some healing occurs within 1-2 weeks, treatment should continue for the full 4-8 weeks to maximize healing rates 1
Context from Guidelines
While sucralfate is effective for duodenal ulcers, current guidelines do not recommend it as first-line therapy because superior alternatives exist 4. Specifically:
- PPIs are the preferred agents for peptic ulcer treatment and prophylaxis 4
- Sucralfate is effective for duodenal ulcers but not effective for preventing or treating NSAID-related gastric ulcers 4
- It may be considered when PPIs are contraindicated or in specific clinical scenarios
Comparative Efficacy
Sucralfate demonstrates comparable efficacy to H2-receptor antagonists (cimetidine, ranitidine) for duodenal ulcer healing 5, 6, with the advantage of minimal systemic absorption and excellent tolerability. The most common side effect is constipation, occurring in only 2-4% of patients 5, 6.